OZANIMOD (Zeposia®)
Clinical Indication
Adults with active disease as part of relapsing-remitting Multiple Sclerosis.
Comments
Not yet reviewed
Date of classification
December 2020
Review date
December 2020
Black
Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.
All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.